Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care

Overview of attention for article published in Trials, July 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)

Mentioned by

news: 1 news outlet

twitter: 15 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 39 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

Comparing the efficacy of duloxetine and nortriptyline in alleviating the symptoms of functional dyspepsia – a randomized clinical trial

Article in Frontiers in Psychiatry (January 2024)

Chinese guidelines for the treatment of chronic pain disorders with non-opioid analgesics

Article in National Medical Journal of China (October 2023)

Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial

Article in The Lancet (October 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.